Chimeric Therapeutics Ltd
ASX:CHM

Watchlist Manager
Chimeric Therapeutics Ltd Logo
Chimeric Therapeutics Ltd
ASX:CHM
Watchlist
Price: 0.004 AUD Market Closed
Market Cap: 7.4m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of CHM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CHM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

N/A
P/S
P/S
Price to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.9
Median 5Y
-6.8
Industry
22.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-6.7
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-6
Industry
22.6
More Details
1.2
P/B
P/B
Price to Book Value
1.2
vs History
83
vs Industry
53
Median 3Y
6.8
Median 5Y
7.7
Industry
2.7
More Details
N/A
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-6.9
Industry
4.5
Forward
-0.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-3
Median 5Y
-6.9
Industry
4.5
Forward
-0.1
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-6.6
Industry
5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-6.6
Industry
3.7
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
92
vs Industry
61
Median 3Y
7.6
Median 5Y
13.2
Industry
4.9
More Details

Multiples Across Competitors

CHM Competitors Multiples
Chimeric Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Chimeric Therapeutics Ltd
ASX:CHM
7.4m AUD 0 -0.4 -0.3 -0.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 936 878.5 -161 297 -195 865.9 -193 630.9
US
Abbvie Inc
NYSE:ABBV
322B USD 5.6 77.5 14.8 21.9
US
Amgen Inc
NASDAQ:AMGN
149B USD 4.4 25.1 13.7 22.6
US
Gilead Sciences Inc
NASDAQ:GILD
137.8B USD 4.8 23.1 10 13.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.4B USD 10.2 -114.7 24.3 25.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 075.9 -529.7 -576.8 -561.4
AU
CSL Ltd
ASX:CSL
113.5B AUD 4.9 27 16.7 20.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.4B USD 4 12.5 11.1 12.5
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.3 -66.1 -59.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
42.1B USD 17.9 -156 -699.8 -350.7
P/S Multiple
Revenue Growth P/S to Growth
AU
Chimeric Therapeutics Ltd
ASX:CHM
Average P/S: 3 393 902.6
Not Available 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 936 878.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.2
10%
1
US
E
Epizyme Inc
F:EPE
2 075.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4
4%
1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.9
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Chimeric Therapeutics Ltd
ASX:CHM
Average P/E: 33
Negative Multiple: -0.4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 297 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.1
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -114.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529.7 N/A N/A
AU
CSL Ltd
ASX:CSL
27
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -156 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Chimeric Therapeutics Ltd
ASX:CHM
Average EV/EBITDA: 15.1
Negative Multiple: -0.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 865.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
13%
1.1
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.3
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.8 N/A N/A
AU
CSL Ltd
ASX:CSL
16.7
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.1
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -699.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Chimeric Therapeutics Ltd
ASX:CHM
Average EV/EBIT: 19.5
Negative Multiple: -0.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 630.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.9
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.5
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561.4 N/A N/A
AU
CSL Ltd
ASX:CSL
20.9
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.5
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -350.7 N/A N/A

See Also

Summary
CHM intrinsic value, competitors valuation, and company profile.
DCF Valuation
CHM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CHM stock valuation using valuation multiples.
Wall Street Estimates
CHM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CHM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 264,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.